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age  57.6 years). Two years after initiation of treatment, 48.7% patients showed 
overall clinical improvement. On average, patients received 367.5 days treatment after
the index date. Patients experienced improvements from baseline in all measures: joint
pain (4.0 vs. 4.3), joint swelling (3.0 vs. 3.2), stiffness (3.6 vs. 3.8), fatigue (4.2 vs. 
4.4), CRP (3.1 vs. 4.1), and ESR (24.5 vs. 31.2) (all P  0.001). Percentages of patients 
improved 1 point were 36.9% (joint pain), 38.0% (joint swelling), 28.2% (stiffness),
27.4% (fatigue), 94.1% (CRP), and 97.5% (ESR). CONCLUSIONS: Understanding 
the real world effectiveness of RA therapies under actual practice conditions is impor-
tant in the treatment decision process. This chart review indicates that inﬂ iximab
therapy had good long-term effectiveness in the treatment of RA. Studies to better 
understand the determinants of treatment adherence beyond clinical effectiveness are 
recommended.
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OBJECTIVES: To evaluate the clinical effectiveness of biologic therapies in the treat-
ment of rheumatoid arthritis (RA) as measured by change in disease severity.
METHODS: Patient self-reported data were collected from the 2008 Rheumatoid 
Arthritis Patient Study. Patients with RA were asked to rate their current disease 
severity (mild, moderate or severe), as well as severity at the time of diagnosis and 
before treatment. Comparisons were made between respondents who received biologic
therapies (abatacept, adalimumab, etanercept, inﬂ iximab, or rituximab) versus those 
treated with non-biologic treatments. An improvement in severity is deﬁ ned as less 
severe (changes from severe/moderate to moderate/mild) after the current treatment. 
RESULTS: Of 2048 respondents to the survey, the mean age was 51.9, and 74.3%
were female. The average duration from RA diagnosis was 11.9 years. For patients 
treated with biologic therapies, the average duration of the treatment was 3.7 years. 
There were no statistical signiﬁ cant differences in age, gender and duration from RA
diagnosis between patients who were treated with a biologic therapy versus those who
were not. At baseline more patients reported their disease status as severe (47.2%) in
the biologic group, compared to patients in the non-biologic group (21.3%). Only 
9.7% of patients in the biologic group versus 29.5% of patients in the non-biologic 
group reported their disease status as mild. However, 44.6% of patients in the biologic 
group versus 25.9% of the non-biologic group reported an improvement in severity 
after the current treatment, while 11.6% of patients in the biologic group versus
15.3% of the non-biologic group reported increased severity in disease state (chi 
square P  0.001) after the current treatment. CONCLUSIONS: In the real world 
setting, RA patients treated with biologic therapies self-reported more severe disease 
than patients treated with non-biologic therapies. Biologic therapies signiﬁ cantly
reduced patient-reported RA disease severity, compared to non-biologic therapies.
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Arthritis of the knee is a real public health problem. Its prevalence is estimated at
6.1% of adults aged over 30 years, according to data from the Framingham Study. 
OBJECTIVES: To observe, in real use conditions, the effects obtained by Hyaluronic
acid in the treatment of arthritis of the knee combined with a prescription of Sodium 
chondroitine sulfate between 2 treatments. METHODS: A longitudinal, prospective
observation programme. RESULTS: Forty-two patients were treated with Hyaluronic
acid and Soduium chondroitine sulfate, 19 patients were treated on the left side 
of the knee and 22 on the right side, with hyaluronic acid. At inclusion, average pain
during daily life activities was 53,289 o 20,836, at W18, 37,963 o 17,173 and at M6,
35,625 o 17,956. Development of the pain during daily life activities between inclusion
and W18 was signiﬁ cant (p  0.0056) as was the same between inclusion and M6
(p  0.0011). At inclusion, average pain at rest was 29,167 o 16,889, at W18, 19,792
o 14,255 and at M6, 19,217 o 17,399. Development of pain at rest between inclusion 
and W18 was not signiﬁ cant (p  0.0594) (however the p-value was very close to
0.05  .  .  .) as was the same between inclusion and M6 (p  0.0619). CONCLUSIONS:
The reduction of the pain – which was signiﬁ cant during patients’ daily activities at
18 weeks, and then sustained at 6 months – is a testimony to the relevance of this
treatment protocol. A greater number of trial subjects would make it possible to
conﬁ rm the signiﬁ cance of the reduction of pain at rest.
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OBJECTIVES: To determine dosing patterns associated with real-world treatment of 
rheumatoid arthritis (RA) patients with inﬂ iximab or abatacept. METHODS: An 
observational, retrospective (cohort) study of patients new to abatacept and inﬂ iximab 
was conducted using the PharMetrics Patient-Centric Database. All adult patients with
at least one claim of RA diagnosis at or prior to initial treatment with inﬂ iximab or 
abatacept from March 2006 to June 2007 were selected. Patients were identiﬁ ed and 
followed for at least 6 months based on their ﬁ rst infusion claim for inﬂ iximab or 
abatacept with no claims for any other biologic in the prior 6 months. Abatacept and 
inﬂ iximab cohorts were compared with respect to baseline characteristics and occur-
rence of upward dose adjustments (increase in dose or frequency). RESULTS: Forty 
abatacept and 216 inﬂ iximab patients were identiﬁ ed as new to biologic therapy. The
two cohorts were generally similar, however 47.5% of initial infusions for abatacept
patients were prescribed by a rheumatologist (also, 15% by primary care physician
(PCP) and 37.5% unknown), compared to 72.7% for inﬂ iximab patients (with 4.6% 
by PCP and 22.6% unknown). Abatacept patients were less likely to experience
upward dose adjustment than inﬂ iximab (10% vs. 57.9%, respectively). Multivariable 
Cox proportional hazards modeling (adjusted for age, gender, Charlson Comorbidity 
Index, and 1-year pre-index RA-related costs) determined that inﬂ iximab patients were 
more likely to experience upward dose adjustment than abatacept patients (HR  5.5, 
95% conﬁ dence interval  2.0–14.9, p  0.001). CONCLUSIONS: Upward dose 
adjustment with some biologic therapies is common and may lead to unexpectedly 
higher treatment costs with additional safety considerations. In this study, upward
dose adjustment appears to be less likely in patients started on abatacept than inﬂ ix-
imab. Further research should determine if the ﬁ xed dosing pattern observed with 
abatacept continues over time, as health care providers and patients become more 
familiar with this biologic.
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OBJECTIVES: Arthritis is the most common chronic illness in the US. Various studies
have found association between arthritis and physical demands of work. This study 
determines the relationship between physical activity at work and prevalence of 
arthritis among working population. METHODS: To distinguish between arthritic
and non arthritic population we used question from the 2007 Behavioral Risk Factor
Surveillance System (BRFSS) that indicates whether an individual was suffering from 
arthritis that had been diagnosed by physician. We also determined an individual level 
of physical activity at work through the question that classiﬁ es an individual level of 
physical activity at work into three levels. RESULTS: The sample consists of 205,533 
respondents out of which (46, 078) 22.42% had arthritis and (15, 9455) 77.58% did
not have any type of arthritis. Results from the logistic regression showed signiﬁ cant 
relationship between prevalence of arthritis and gender, age, race, education, income,
reported health status, BMI, health coverage and physical activity at work (A  0.05). 
There was inconsistent relationship among the level of physical activity and prevalence 
of arthritis as people having moderate physical activity had lesser odds (O.R.0.965, 
95% CI: 0.938–0.994) of suffering from arthritis i.e. one unit increase in moderate 
physical activity at work was associated with 3.5% decrease in the odds of suffering 
from arthritis. However, people having heavy physical activity at work had greater
odds of (O.R.1.265, 95% CI: 1.220–1.311) of suffering from arthritis indicating that 
one unit increase in heavy physical activity was associated with 27% increase in the 
odds of suffering from arthritis. CONCLUSIONS: There is a need to investigate in 
greater detail the role of physical activity at work in conjunction with other factors 
on the prevalence of arthritis. This investigation can help in identifying people sus-
ceptible to develop arthritis along with the factors responsible for their illness.
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CONTEXT: Fibromyalgia syndrome (FMS) is an under-diagnosed. OBJECTIVES: To 
describe Russian rheumatologists’ knowledge of ﬁ bromyalgic patients. METHODS:
The questionnaire was sent to a random sample of Russian practitioners, who were 
answering the same questionnaire as that used by French practitioners in 2003.
RESULTS: The average number of patients seen daily by each practitioner was 58
(median 36 patients) 88% and 75% of the doctors claimed, individually, that they 
had not received any education on ﬁ bromyalgia or chronic fatigue during their medical
studies. During their professional activity, 53.9% of the doctors have still not had any
professional training on ﬁ bromyalgia. One percent of the doctors believed that ﬁ bro-
myalgia does not exist, while 36.5% believed that ﬁ bromyalgia is an illness and 63.2%
that it is a syndrome. Forty percent of the doctors who answered were continuing to 
treat ﬁ bromyalgic patients, 28% referred them to a specialist rheumatologist, 14% to 
a neurologist and 9% to a psychiatrist. Excessive fatigue, diffuse pain, a tendency
to feel depressed, anxious and sad, and muscle weakness were recognised respectively
as being the main symptoms of ﬁ bromyalgia by 64, 77, 64 and 45 % of the rheuma-
tologists respectively. Digestive problems, palpitations, swollen joints and radiological 
irregularities were recognised as being the main symptoms of ﬁ bromyalgia by 10, 13, 
12 and 9% of the rheumatologists respectively. CONCLUSIONS: As in EC countries, 
a wide-scale training effort should be made in order to improve the diagnosing of 
patients. The data collected via these evaluations was close to the results for France.
